Abstract
POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is a rare cause of demyelinating and axonal neuropathy and multi-organ involvement, associated with plasma cell dyscrasia and upregulation of serum levels of vascular endothelial growth factor (VEGF). The pathogenesis of the disorder is not well understood, but increased vascular permeability and neovascularization mediated by VEGF and other inflammatory cytokines are likely to play an important role in most of the characteristic symptoms. However, the pathogenesis of peripheral neuropathy is unclear; VEGF may affect the blood-nerve barrier and allow neurotoxic substances to access the nerve parenchyma, resulting in nerve structural damages. POEMS syndrome is a potentially fatal disease, and there is no established treatment regimen for this syndrome. In appropriate candidates, high-dose chemotherapies with autologous peripheral blood stem cell transplantation are recommended, because this treatment can lead to obvious and rapid clinical improvement in neuropathy as well as other symptoms, with a significant decrease in serum VEGF levels. The indication for this treatment has not yet been established, and the long-term prognosis is unclear. Potential future therapies include the administration of thalidomide, lenalidomide, bortezomib, and anti-VEGF monoclonal antibody (bevacizumab). Prognosis of POEMS syndrome has been substantially improved by these novel interventions, whereas randomized control trials are required to establish a proper therapeutic guideline. This review focuses on recent advances in diagnosis and treatment of POEMS syndrome and discusses future perspectives of therapeutic strategy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes: the POEMS syndrome. Report of two cases and a review of the literature. Medicine. 1980;59:311–22.
Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984;34:712–20.
Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6, CD006828.
Isose S, Misawa S, Kanai K, et al. POEMS syndrome with Guillan-Barre syndrome-like acute onset: a case report and review of neurological progression in 30 cases. J Neurol Neurosurg Psychiatry. 2011;82:678–80.
Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, Fujimaki Y, Ohmori S, Mitsuma S, Koga S, Kuwabara S. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012;83:476–9.
Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347:702.
Kanai K, Sawai S, Sogawa K, Mori M, Misawa S, Shibuya K, et al. Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology. 2012;79:575–82.
Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496–506.
Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology. 2008;71:1691–5.
Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:804–14.
Li J, Zhou DB. New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol. 2013;161:303–15.
D’Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118:4663–5.
Shibuya K, Misawa S, Horikoshi T, Kanai K, Isose S, Nasu S, Sekiguchi Y, Noto Y, Fujimaki Y, Nakaseko C, Kuwabara S. Detection of bone lesions by CT in POEMS syndrome. Intern Med. 2011;50:1393–6.
Gandhi GY, Basu R, Dispenzieri A, Basu A, Montori VM, Brennan MD. Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:836–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Kuwabara, S., Misawa, S. (2016). POEMS Syndrome. In: Kusunoki, S. (eds) Neuroimmunological Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55594-0_12
Download citation
DOI: https://doi.org/10.1007/978-4-431-55594-0_12
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55593-3
Online ISBN: 978-4-431-55594-0
eBook Packages: MedicineMedicine (R0)